Long‐term survival benefit of upfront chemotherapy in patients with newly diagnosed borderline resectable pancreatic cancer

The use of neoadjuvant chemotherapy or radiation for borderline resectable pancreatic adenocarcinoma (BL‐PDAC) is increasing. However, the impact of neoadjuvant chemotherapy and radiation therapy on the outcome of BL‐PDAC remains to be elucidated. We performed a retrospective analysis of 93 consecut...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Cancer Med
Autori principali: Shrestha, Bikram, Sun, Yifei, Faisal, Farzana, Kim, Victoria, Soares, Kevin, Blair, Alex, Herman, Joseph M., Narang, Amol, Dholakia, Avani S., Rosati, Lauren, Hacker‐Prietz, Amy, Chen, Linda, Laheru, Daniel A., De Jesus‐Acosta, Ana, Le, Dung T., Donehower, Ross, Azad, Nilofar, Diaz, Luis A., Murphy, Adrian, Lee, Valerie, Fishman, Elliot K., Hruban, Ralph H., Liang, Tingbo, Cameron, John L., Makary, Martin, Weiss, Matthew J., Ahuja, Nita, He, Jin, Wolfgang, Christopher L., Huang, Chiung‐Yu, Zheng, Lei
Natura: Artigo
Lingua:Inglês
Pubblicazione: John Wiley and Sons Inc. 2017
Soggetti:
Clinical Cancer Research
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5504321/
https://ncbi.nlm.nih.gov/pubmed/28639410
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.1104
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi